Dual checkpoint inhibitors led to longer overall survival in patients with high-risk endometrial cancer who displayed ...

About Adagene Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer ...

BioAtla is laying off 30% of staff as the biotech searches for partners for some of its conditionally active biologic (CAB) ...

Two neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single drug, a small randomized trial showed. The pathologic tumor response (pTR) ...

Xilio Therapeutics (NASDAQ:XLO – Get Free Report) is projected to announce its earnings results before the market opens on Monday, April 7th. Analysts expect the company to announce earnings of ($0.22 ...

Reports revenue $103,204 vs. $18.1M last year. “The clinical data we generated in 2024 with ADG126 gives us great confidence in our ability to ...